What Is INNOVEYES SightMap™ Technology, and Why Does It Matter for LASIK?

Gregg Feinerman MD, FACS

April 7, 2026Medically reviewed by Gregg Feinerman, MD, FACS · September 19, 2026

When most people think about LASIK, they think about the laser. The quality of the result depends just as much on what happens before the laser turns on: how completely your eye is measured, and how that measurement is turned into a treatment plan.

INNOVEYES SightMap™ is the diagnostic device behind WaveLight® Plus LASIK. It is the reason WaveLight Plus can plan a treatment from a three-dimensional model of your own eye rather than from your glasses prescription. This article explains what SightMap measures, how ray tracing turns those measurements into a laser plan, what the published research shows, and what the scan is like from the patient’s side.

The short answer. SightMap is a single instrument, made by Alcon, that combines three measurements of your eye (corneal tomography, whole-eye wavefront aberrometry, and optical biometry) into one session and builds a virtual model of your eye from more than 100,000 data points. WaveLight Plus then traces thousands of simulated light rays through that model to calculate a corneal reshaping that is specific to your eye. In the FDA study of 334 eyes, 94.4% saw 20/20 or better without glasses at one year, and in two large clinical series every treated eye reached 20/20. It does not treat the lens inside the eye and it does not make anyone immune to halos, but it is the most complete measurement of the eye that any LASIK platform has ever used to plan a treatment.

What SightMap Actually Measures

Older LASIK planning starts with your manifest refraction, the “which is better, one or two” prescription, and applies a standard correction profile to the cornea. Customized platforms added a map of the front of the cornea (topography-guided) or a measurement of the eye’s optical errors (wavefront-guided). Each of those captures one part of the picture.

SightMap captures three parts in one sitting. According to Alcon’s technical description and the peer-reviewed methods papers, the device contains a Scheimpflug tomographer, a Hartmann-Shack wavefront sensor, and a partial coherence interferometry biometer, and a typical evaluation includes several repeated captures of each. [1, 2] Together they record:

The shape and curvature of the front and back surfaces of the cornea (tomography), which is where the laser will work.
The eye’s total optical errors, including higher-order aberrations (wavefront aberrometry). Higher-order aberrations are small, irregular focusing errors that glasses cannot correct. They matter most when the pupil is large, which is why they are linked to halos, starbursts, and reduced contrast at night.
The internal dimensions of the eye (biometry): the depth of the front chamber, the position of the front surface of the natural lens, and the total length of the eye from cornea to retina.

From those measurements the software builds what Alcon calls a “digital eye twin,” a virtual three-dimensional model of your individual eye. [3] The point of measuring the internal dimensions is not to treat the lens; it is to know exactly where every surface sits so that the simulation of light passing through the eye is accurate for your anatomy rather than for a textbook average.

How Ray Tracing Turns the Map Into a Treatment

Ray tracing is a method borrowed from optical engineering. Instead of asking “what prescription does this eye need,” the software asks “what shape must the front of this cornea be so that light entering through this pupil, passing through this cornea, this chamber, and this lens, lands sharply on this retina.” It then simulates thousands of light rays through the model, adjusts the proposed corneal shape, and repeats until the rays converge as tightly as possible. Surgeons who use the system describe on the order of two thousand rays being traced per eye. [23]

Three details separate this from earlier planning methods. First, the treatment is calculated from objective measurements only; the manifest refraction is used to confirm the scan, not to drive the laser, and the calculation runs without surgeon nomogram adjustments. [2, 3] Second, the algorithm models the whole eye, so it can target the total optical error of the eye rather than the cornea alone. [1] Third, the ablation profile includes compensation for how laser energy falls off toward the edge of the treatment zone, how the corneal epithelium remodels after surgery, and how the cornea responds mechanically to tissue removal. [1] A 2026 study of 60 eyes found that ray-tracing-guided LASIK preserved the cornea’s natural asphericity and lowered spherical aberration across the whole optical zone compared with a Q-value-adjusted treatment, which is the mechanism those compensations are designed to produce. [5]

The calculation that once took hours on early ray-tracing prototypes now takes seconds at the laser. [4] That is what allowed the approach to move from research into routine clinical use.

What SightMap Does Not Do

A few claims about this technology circulate online, so it is worth being precise about its limits.

SightMap measures the lens; it does not treat it. LASIK reshapes the cornea only. The whole-eye measurement lets the corneal reshaping compensate for optical errors that originate deeper in the eye, but it cannot change the lens, and it cannot prevent the lens from aging. That is why Dr. Feinerman generally does not recommend LASIK over 45; the aging lens, not the cornea, is usually the real problem at that age.

SightMap-guided treatment is not “pupil-independent.” Higher-order aberrations affect vision mainly when the pupil is large, so the benefit of treating them shows up most in low light and in patients with larger pupils. In the randomized trial against Wavefront Optimized LASIK, the difference in aberrations between the two treatments was clear at a 6 mm pupil and mostly disappeared at 4.5 mm. [2] The technology works with the pupil, not around it.

And no published study has yet shown that WaveLight Plus produces better patient-reported night vision than another platform in a direct comparison. What the studies show is a consistent optical result (lower spherical aberration, in several series lower trefoil) that is plausibly connected to night-vision quality, plus, in the FDA study, a drop in reported visual symptoms compared with before surgery. [6, 7] Those are strong findings. They are not the same as a head-to-head night-driving trial, and this article will not describe them as one.

How SightMap Compares With Earlier LASIK Planning

Planning method	What it measures	What it corrects	Where it falls short
Wavefront Optimized (WFO)	Manifest refraction	Sphere and cylinder, with a standard profile that limits induced spherical aberration	Does not measure or treat the eye’s existing higher-order aberrations
Wavefront-guided	Whole-eye wavefront	Sphere, cylinder, and measured aberrations	Uses a generic eye model to convert the wavefront into a corneal shape; studies have not shown it to clearly outperform WFO
Topography-guided (Contoura® Vision)	Front corneal surface	Corneal surface irregularities plus sphere and cylinder	Does not measure internal optics; surgeon must reconcile corneal and manifest astigmatism
Ray-tracing-guided (WaveLight® Plus with SightMap)	Front and back cornea, whole-eye wavefront, internal dimensions, eye length	Total optical error of the eye, calculated on a model of that eye	Approved in the US for myopia only; scan must agree with the manifest refraction (the prescription measured at your consultation); effect on aberrations is largest at big pupils

The table is a summary of how each method is designed, not a claim that every patient sees a different result. The section below covers what has actually been measured.

What the Research Shows

Ray-tracing-guided LASIK now has a substantial evidence base, and it has grown quickly since FDA approval in March 2025. [8] The studies below are the ones that matter most for a patient deciding whether the technology is worth choosing.

The FDA study (334 eyes analyzed, 9 US sites, 12 months). This is the prospective trial that led to US approval. At refractive stability, 92.3% of eyes saw 20/20 or better without glasses, rising to 94.4% at 12 months; 92% were within half a diopter of the target. No eye lost two or more lines of best-corrected vision at stability, and no eye was retreated during the study. Contrast sensitivity under glare improved in 48% of eyes at 12 months. The proportion of patients reporting any visual symptom fell from 77.8% before surgery to 35% at 12 months, moderate-to-severe dry-eye scores fell from 24.5% to 5.5%, and 97.5% of patients were very or completely satisfied. [6, 8]

Real-world outcomes (400 eyes, Australia). In a consecutive series of 200 patients, every eye reached 20/20 or better, 89% reached 20/16, and 50% reached 20/12.5 at three months. [9] This is the series most often quoted for the platform, including on this site, and it remains the largest published real-world cohort.

One-year prospective study (800 eyes, India, 2026). Published in the American Journal of Ophthalmology in September 2026, this is the largest WaveLight Plus study to date and the first large series with a full year of follow-up. At 12 months, 100% of eyes saw 20/20 or better and 68% saw 20/16 or better; 96.5% were within half a diopter of target; only 0.38% of eyes drifted more than half a diopter between one month and one year; and in a 300-eye subgroup with 1.50 diopters or more of astigmatism, 91.7% ended with 0.50 diopters or less of residual astigmatism. [10]

Meta-analysis (14 studies, 1,577 eyes, 2026). Pooling the published studies, 99.2% of eyes reached 20/20 or better without glasses, loss of one or more lines of best-corrected vision occurred in 2.2%, and best-corrected vision improved in nearly half of eyes. Total higher-order aberrations rose slightly on average (by 0.087 micrometers) while spherical aberration and trefoil tended to fall. The authors note that most studies are short-term and call for longer follow-up. [7]

Randomized trial against Wavefront Optimized LASIK (60 eyes, Germany). Each of 30 patients had WaveLight Plus in one eye and Wavefront Optimized LASIK in the other, chosen at random, with both patient and examiner masked. At three months, 100% of WaveLight Plus eyes and 93.3% of WFO eyes saw 20/20 or better, and 100% versus 90% were within half a diopter of target. Higher-order aberrations did not change after WaveLight Plus but rose after WFO at a 6 mm pupil. The acuity differences did not reach statistical significance in a study of this size; the aberration difference did. [2]

Comparisons with topography-guided LASIK. A randomized trial of 84 eyes found better uncorrected vision after ray-tracing-guided treatment (48% at 20/12.5 versus 5%) and a reduction in spherical aberration that topography-guided treatment did not produce. [11] A separate analysis comparing the two FDA approval datasets found the platforms equal at 20/20 and 20/16, topography-guided ahead at 20/12.5, and ray tracing well ahead on contrast sensitivity under glare (40% of eyes gaining versus 23.8%). [12] A third comparison, 100 eyes split between the two methods, found the same pattern: equal efficacy and safety indices, but spherical aberration fell only in the ray-tracing group, and that negative shift was associated with fewer starburst complaints. [24] In other words, the two Alcon platforms are close on the eye chart, and every direct comparison has put ray tracing ahead on the optical quality measures that matter in low light.

Comparison with SMILE Pro. In a paired-eye series presented at the American Academy of Ophthalmology meeting in October 2025, 98% of WaveLight Plus eyes reached 20/12.5 or better compared with 82% of SMILE Pro eyes, with every WaveLight Plus eye within a quarter diopter of target. [13] A separate published single-surgeon series found 98% of WaveLight Plus eyes at 20/20 or better versus 74% of SMILE Pro eyes at three months, with lower residual astigmatism after WaveLight Plus and no difference in safety indices. [14] Both are early, non-randomized comparisons, and neither measured night vision directly.

Taken together: the eye-chart results of WaveLight Plus are as good as any LASIK platform has reported, its refractive accuracy and one-year stability are excellent, and its distinctive result is optical, a consistent reduction in spherical aberration that other planning methods have not matched in direct comparison.

What the Scan Is Like, and Why It Sometimes Has to Be Repeated

The SightMap evaluation is part of your consultation, before any treatment decision. It is non-contact and painless. You look into the instrument while it captures a series of images; a full set includes several wavefront captures, two tomography scans, and a biometry reading for each eye. [2] In a published series of 1,283 eyes, the scanning time per eye averaged about eight to eleven minutes early in a practice’s experience and fell as the staff gained experience. [15]

There is one thing worth knowing in advance. Younger eyes can strain to focus involuntarily during the scan (a reflex called accommodation), which makes the wavefront reading come out more nearsighted than your true prescription. In that same 1,283-eye series, the wavefront reading was more than half a diopter more myopic than the manifest refraction in 21.4% of eyes. [15] Because the treatment is calculated from the scan, the FDA study required the scan and the manifest refraction to agree within 0.75 diopters, and that agreement is part of the labeled candidacy criteria in the United States. [8]

When the two disagree, surgeons have well-documented options: repeating the scan after dilating drops, which relax the focusing muscle so eye strain cannot skew the measurement, or adjusting the treatment toward the manifest refraction. At Feinerman Vision, if the SightMap reading and the manifest refraction differ by more than 0.75 diopters of spherical equivalent, the scan is routinely repeated under dilation before any treatment is planned. In the 1,283-eye series, 98% of surgeon-adjusted eyes and 96% of eyes treated from a dilated scan reached 20/20 or better. [15] Two 2025 studies designed specifically around eyes whose scans disagreed with their manifest refraction by more than 0.50 or 0.75 diopters reported 98% to 100% of eyes at 20/20 or better after adjustment. [16, 17] A randomized study also found that a brief accommodation exercise before scanning raised the share of eyes whose SightMap reading matched their manifest refraction within half a diopter from 56% to 88%. [18] The practical point for patients: a repeat scan or a dilated scan is normal, not a sign that something is wrong.

Who Benefits Most From SightMap-Guided LASIK

Every WaveLight Plus patient is treated from a SightMap model, so every patient gets the eye-specific calculation. The published data suggest a few groups where the difference from older planning is most likely to show:

Patients with astigmatism. The 800-eye one-year study included a 300-eye subgroup with 1.50 diopters or more of cylinder, and 85% of those eyes ended within 5 degrees of the intended axis. [10] A 60-eye comparison in eyes with 2.00 diopters or more found 87% of ray-tracing eyes within a quarter diopter of cylinder versus 63% with a Q-value-adjusted treatment. [19]
Patients with higher myopia. In a 77-eye series averaging -7.5 diopters, 100% of eyes reached 20/20 with no loss of best-corrected vision, and spherical aberration did not increase despite the deep correction. [20] A separate series found that the fall in spherical aberration after treatment was associated with fewer starburst complaints in highly myopic eyes. [21]
Patients with larger pupils or existing night-vision complaints. The aberration differences between platforms show up at large pupil sizes. [2] This is the group most likely to notice the optical difference, though no study has yet measured that in a head-to-head night-driving comparison.
Patients whose best-corrected vision is not quite 20/20 in glasses. Across the studies, a large share of eyes ended up seeing better without correction than they did with glasses beforehand: 62.8% gained at least one line in a 285-eye series, and nearly half improved in the pooled meta-analysis. [7, 22]

SightMap does not change who is a LASIK candidate at the most basic level. The cornea still needs to be healthy and thick enough, the prescription stable, and the scan must agree with the manifest refraction. In the United States the platform is approved for nearsightedness with or without astigmatism (spherical equivalent up to -9.00 diopters, cylinder up to -3.00 diopters) and is not yet available for farsightedness. [8] Patients outside that range, or with corneas too thin for LASIK, are usually better served by EVO ICL™, and Dr. Feinerman evaluates candidacy across every modern option before recommending one.

SightMap at Feinerman Vision

Dr. Gregg Feinerman was the first surgeon in Orange County and greater Los Angeles to perform WaveLight Plus LASIK after its FDA approval in 2025. WaveLight Plus runs here on the WaveLight® EX500 excimer laser with the Ziemer FEMTO LDV Z8 femtosecond laser for the flap. Every WaveLight Plus evaluation begins with a SightMap scan, and Dr. Feinerman reviews the scan and its agreement with your refraction personally before any treatment recommendation is made. If the two differ by more than 0.75 diopters, the scan is repeated under dilation.

WaveLight Plus LASIK is $5,100 for both eyes, all-inclusive, and includes the lifetime enhancement guarantee. Prices are subject to change. LASIK, PRK, EVO ICL, and refractive lens exchange consultations are free.

Frequently Asked Questions

Is SightMap the same as a wavefront scan?

No. A wavefront scan is one of the three measurements SightMap takes. SightMap also maps both corneal surfaces and measures the internal dimensions and length of the eye, and it uses all of that to build a model of your eye for ray tracing. A wavefront-guided treatment uses the wavefront alone with a generic eye model.

Does SightMap treat problems inside the eye?

No. It measures the whole eye so the corneal reshaping can compensate for the eye’s total optical error, but LASIK only changes the cornea. It cannot correct or prevent age-related changes in the lens.

What happens if my SightMap scan does not match my manifest refraction?

It is common, especially in younger patients whose eyes strain to focus during the scan. At Feinerman Vision, a difference of more than 0.75 diopters means the scan is repeated under dilation, which relaxes the focusing muscle so eye strain cannot affect the measurement. Published results after a repeated or dilated scan are excellent. If the two cannot be reconciled within the labeled limit, Dr. Feinerman will discuss other options with you.

Is SightMap available for farsightedness?

Not in the United States. WaveLight Plus is currently approved for nearsightedness with or without astigmatism. Farsighted patients have other options, including Wavefront Optimized LASIK and lens-based procedures.

SCHEDULE YOUR CONSULTATION

Dr. Feinerman personally reviews every SightMap evaluation · Newport Beach, CA · (949) 631-4780

References

Alcon Science. Sightmap and Wavelight Plus technology (technical resource). Accessed September 19, 2026. https://www.alconscience.com/en-IN/resource/sightmap-and-wavelight-plus-technology/
Khoramnia R, Naujokaitis T, Blöck L, et al. Prospective intraindividual comparison of automated customized ray-tracing-guided versus wavefront-optimized LASIK. Ophthalmology. 2025;132(10):1169-1179. https://doi.org/10.1016/j.ophtha.2025.05.025
Alcon. Alcon announces first fully personalized LASIK treatment with wavelight plus in the U.S. and Canada. Media release, September 9, 2025. https://www.alcon.com/media-release/alcon-announces-first-fully-personalized-lasik-treatment-wavelight-plus-us-and-canada/
Hillman L. The evolution of LASIK treatment planning. EyeWorld. July 7, 2026. https://www.eyeworld.org/2026/the-evolution-of-lasik-treatment-planning/
Zhao B, Yuan B, Liu Y, Guo X, Chai J, Zhang H. Corneal asphericity preservation via spatially selective peripheral stromal volume ablation following ray-tracing-guided LASIK. J Refract Surg. 2026;42(7). https://doi.org/10.3928/1081597X-20260415-01
Krueger RR, et al. Myopic and astigmatic laser in situ keratomileusis using a ray tracing-based treatment algorithm with a personalized ablation profile. Clin Ophthalmol. 2026;20:567933. https://doi.org/10.2147/OPTH.S567933
Friedrich M, Augustin VA, Auffarth GU, Khoramnia R, Son HS. Visual outcomes and safety of ray-tracing-guided laser-assisted in situ keratomileusis: a systematic review and meta-analysis. Ophthalmol Ther. 2026. https://doi.org/10.1007/s40123-026-01376-3
U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data, P020050/S043 (WaveLight EX500 with InnovEyes Sightmap). Approved March 5, 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf2/P020050S043B.pdf
He G, Bala C. Ray-tracing-guided myopic LASIK: real-world clinical outcomes. J Cataract Refract Surg. 2023;49(11):1140-1146. https://doi.org/10.1097/j.jcrs.0000000000001286
Shetty R, Shah A, Singh P, et al. Stability, safety, and efficacy of WaveLight Plus InnovEyes ray-tracing-guided LASIK in myopia and myopic astigmatism: a one-year prospective study. Am J Ophthalmol. 2026 Sep 10:S0002-9394(26)00510-6. Online ahead of print. https://doi.org/10.1016/j.ajo.2026.09.006
Cao X, Zhang J, Shao J, Zhang Y, Zheng L. Study of the InnovEyes Sightmap platform in comparing ray-tracing-guided LASIK and topography-guided LASIK. J Refract Surg. 2024;40(12):e994-e1002. https://doi.org/10.3928/1081597X-20241030-03
Sitto MM, Moshirfar M, Crook TB, Hoopes PC. Comparison of U.S. FDA premarket approval studies between ray tracing-guided LASIK with InnovEyes Sightmap versus topography-guided LASIK using custom ablation treatment (T-CAT). Ophthalmol Ther. 2025;14(12):2983-3005. https://doi.org/10.1007/s40123-025-01245-5
Kanellopoulos AJ. Contralateral comparison of ray-tracing-guided LASIK and SMILE Pro. Presented at the 129th Annual Meeting of the American Academy of Ophthalmology, October 2025, Orlando, FL. Meeting presentation; not yet published in a peer-reviewed journal. Summary: https://www.aao.org/newsroom/news-releases/detail/latest-evolution-of-lasik-technology-shows-results
Molleti S, et al. Initial visual and refractive outcomes of ray-tracing-guided LASIK (Wavelight Plus) versus KLEx (SMILE Pro). Ophthalmol Ther. 2026;15:3401-3419. https://doi.org/10.1007/s40123-026-01475-1
Thananjeyan AL, Bala C. Factors affecting ray trace LASIK data acquisition in clinical practice: options for addressing accommodation. Clin Ophthalmol. 2025;19. https://doi.org/10.2147/OPTH.S524774
Tan S, Fan Y, Wang X, Luo L, Zhang Y, Liu Z. Ray-tracing-guided FS-LASIK using Mi optimized strategies. J Refract Surg. 2025;41(12). https://doi.org/10.3928/1081597X-20251023-01
Wang Y, Zhang Y, Pan J, Wang J, Fang X. Refractive outcome and visual quality of ray-tracing guided LASIK: a prospective study. BMC Ophthalmol. 2025;25. https://doi.org/10.1186/s12886-025-04517-7
Jin C, Wang S, Ye H, Wei R, Dong Y, Zhao P. Effects and related factors of short-time accommodation training on measuring consistency of InnovEyes Sitemap, autorefraction, and subjective refraction. J Refract Surg. 2024;40(12):e941-e955. https://doi.org/10.3928/1081597X-20241022-01
Luo L, Fan Y, Wang X, Hu Q, Cai Y, Yang L. Ray-tracing-guided versus Q-value-adjusted LASIK for myopic astigmatism of 2.00 diopters or greater: 3-month clinical outcomes. Photodiagnosis Photodyn Ther. 2026. https://doi.org/10.1016/j.pdpdt.2026.105412
Luo L, Fan Y, Wang X, Yang L, Tan S, Zhang Y. Ray tracing-guided LASIK for high myopia and astigmatism: initial clinical outcomes. Photodiagnosis Photodyn Ther. 2025. https://doi.org/10.1016/j.pdpdt.2025.104715
Huang Y, Li J, Zhang F, Song Y, Xu Y, Zhang Y. Changes of refraction and visual quality after ray-tracing guided FS-LASIK in Chinese high myopia versus low-to-moderate myopia. Photodiagnosis Photodyn Ther. 2025. https://doi.org/10.1016/j.pdpdt.2025.105216
Shi R, Zhao W, Zhu L. Ray-tracing-guided LASIK: refractive and visual outcomes and the role of higher order aberrations in visual gain. J Refract Surg. 2026;42(8):e804-e814. https://doi.org/10.3928/1081597X-20260508-03
Review of Ophthalmology. What does ray tracing-guided LASIK have in store? February 11, 2026. https://www.reviewofophthalmology.com/article/what-does-ray-tracingguided-lasik-have-in-store
Ao D, Wu J, Zhang B, Xiong L, Wang Z. Ray-tracing guided versus topography-guided FS-LASIK for myopia: a comparative study of relative peripheral refraction and visual quality. BMC Ophthalmol. 2026. https://doi.org/10.1186/s12886-026-04921-7

Ready to see life more clearly?

Call us at (949) 631‑4780 or schedule your consultation online to discover why patients across Orange County choose Feinerman Vision for personalized vision care from the surgeon himself.